Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363403 | 1.00 | SLC6A4 (1.00) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| Phosphoric Acid SCHEMBL8111167 | 0.96 | SLC6A4 (0.93) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL7794028 | 0.91 | SLC6A4 (0.84) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL7795679 | 0.90 | SLC6A4 (0.81) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL7797288 | 0.89 | SLC6A4 (0.81) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL7793815 | 0.89 | SLC6A4 (0.80) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL7796909 | 0.88 | SLC6A4 (0.79) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL8117843 | 0.87 | SLC6A4 (0.78) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL7793808 | 0.87 | SLC6A4 (0.76) | SLC6A4HTR2AKDM4EGMNNALDH1A1 | |
| SCHEMBL7793813 | 0.87 | SLC6A4 (0.76) | SLC6A4HTR2AKDM4EGMNNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010053783-A1 | Central nervous system disorders | FAIRHURST JOHN (GB) | 2001-12-20 | — | — | US | claimed |
| EP-0854146-B1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-03-15 | — | — | EP | claimed |
| EP-0854146-A1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-22 | — | — | EP | claimed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | disclosed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigacions Cientificas (CSIS) (ES) | 2020-12-24 | — | — | US | disclosed |
| EP-3713568-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-09-30 | — | — | EP | disclosed |
| US-20200121620-A1 | SENOLYTIC COMPOUNDS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2020-04-23 | — | — | US | disclosed |
| US-8835436-B2 | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2014-09-16 | — | — | US | disclosed |
| US-8835436-B2 | Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2014-09-16 | — | — | US | disclosed |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2012-09-13 | — | — | US | disclosed |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2012-09-13 | — | — | US | disclosed |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-05-10 | — | — | US | disclosed |
| WO-2011059207-A2 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | GREEN CROSS CORPORATION (KR) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011005052-A2 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN GROSS CORPORATION (KR) | 2011-01-13 | — | — | WO | disclosed |
| US-20010053783-A1 | Central nervous system disorders | FAIRHURST JOHN (GB) | 2001-12-20 | — | — | US | disclosed |
| EP-0854146-B1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | LILLY CO ELI (GB) | 2000-03-15 | — | — | EP | disclosed |
| EP-0854146-A1 | Substituted 4-(6-fluoro-[1H]-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders | ELI LILLY AND COMPANY LIMITED (GB) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | SLC6A4 27/4885HTR2A 1/4885KDM4E 2536/4885 |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | SLC6A4 28/4885HTR2A 1/4885KDM4E 2569/4885 |
| US-20120232090-A1 | ARYLPIPERAZINE-CONTAINING PURINE DERIVATIVES AND USES THEREOF | ADORA2A, P2RX5, PNP | SLC6A4 76/4885HTR2A 17/4885KDM4E 2434/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | SLC6A4 27/4885HTR2A 1/4885KDM4E 2536/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | SLC6A4 27/4885HTR2A 1/4885KDM4E 2536/4885 |
| US-20120115881-A1 | NOVEL ARYLPIPERAZINE-CONTAINING IMIDAZOLE 4-CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HTR2C, HTR5A, HTR2A | SLC6A4 35/4885HTR2A 3/4885KDM4E 399/4885 |
| US-20200121620-A1 | SENOLYTIC COMPOUNDS | PINK1, PTK2, FYN | SLC6A4 3094/4885HTR2A 3567/4885KDM4E 1015/4885 |
| US-20010053783-A1 | Central nervous system disorders | CNR1, PMP22, CNR2 | SLC6A4 126/4885HTR2A 332/4885KDM4E 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.